Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract
Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.
You may also be interested in...
FDA and NIH officials propose three strategies for clinical trials, saying it will be challenging to identify the most promising candidates; Sanofi and Walter Reed researchers note challenges in vaccine development, including manufacturing scale up.
Takeda and Zydus Cadila are stepping into the fray to develop a vaccine for chikungunya, an increasingly crowded segment that now has over a dozen candidates in various stages of development.
While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.